Welcome: Paul A. Volberding, MD and Warner Greene, MD, PhD
Opening Address
- Haile T. Debas, MD
Dean, School of Medicine, University of California San Francisco
Morning Session
Moderator: Charles S. Craik, PhD
- Geographical variation of HIV 1 and HIV 2: indications for vaccine development
Max Essex, DVM, PhD, Harvard AIDS Institute - Development of Novel Anti-HIV Agents; PMPA
Norbert W. Bischofberger, PhD, Gilead Sciences - HIV-1 Protease Inhibitors: What have we learned and what is in the future?
James Kahn, MD, Associate Professor of Medicine, UCSF; Associate Director, UCSF Center for AIDS Research - Mechanisms and Therapeutic Implications of Drug Resistance to HIV-1 Protease Inhibitors
John Erickson, PhD, Director, Structural Biochemistry Program, NCI-Frederick Cancer Research and Development Center - An Overview of Viral Kinetics as it Relates to the Potential for Eradicating HIV
George M. Shaw, MD, PhD, Professor of Medicine and Microbiology; Deputy Director UAB AIDS Center U of Alabama at Birmingham
Afternoon Session
Moderator: John Greenspan, BDS, PhD
- New Agents and Targets for HIV-modulation
H. Clifford Lane, MD, Clinical Director, NIH/NIAID - Use of Animal Models to Study Pathogenesis of Primate Lentivirus Infection and Treatment Concepts
Shiu-Lok Hu, PhD, Executive Director Immunodeficiency/Immunosuppression, Bristol-Myers Squibb Pharmaceutical Research Institute - Towards in vivo Gene Therapy for HIV Infection
Flossie Wong-Staal, PhD, Departments of Medicine and Biology, University of California, San Diego; Director, AIDS Research Institute - Gene Therapy Involving Rev Transdominants
Gary Nabel, MD, PhD, Howard Hughes Medical Institute - What is the Future of Gene Therapy to Modulate HIV Disease?
Lewis T. ("Rusty") Williams, MD, Chiron/UCSF - Summary: Warner C. Greene, MD, PhD